PRODUCED BY
PRODUCED BY
ERIC GOLDSTEIN King of Prussia District Executive Director
GET $15 OFF KING’S PLATE TICKETS ON OCT. 3 Use code BIG3KING
GET $5 OFF MAIN EVENT TICKETS ON OCT. 5 Use code BIG3MAIN
THANK YOU SPONSORS
APPI energy
DENNIS LAVASSEUR Bryn Mawr Insurance Advisors SVP & Sales Manager
TOM MCGRATH Philadelphia magazine Editor
ELIZABETH SMITH SEPTA Director of Strategic Planning & Analysis
KOP Rail
KOP BID Big 3 Breakfast September 19, 2019
9
Project Background King of Prussia not currently served by rail
Off the grid!
•  Served by 6 bus routes with high ridership, but low on-time performance and long trip times
10
Locally Preferred Alternative (LPA)
11
Locally Preferred Alternative (LPA)
12
Promotes and Strengthens Regional Growth 60,000 jobs
75,000 jobs
292,000 jobs
13
Promotes and Strengthens Regional Growth
14
Convenient and Reliable Way to Connect People to Opportunities • Alternative to Schuylkill Expressway and congested local roads • Quick and convenient reverse commute • Reduces current commute times by 30 minutes each way
Six bus routes
Lower rate of licensed drivers
5,600 riders 65% on-time
NHSL
99% on-time No Schuylkill traffic
15
Essential to Support Evolving Needs • Responds to growing mobility needs of millennials, seniors, and persons with disabilities • Strategically directs existing and future growth
TOD Potential KOP Rail
KOP Mall
16
Project Schedule We are Here
2013
2018
Alternatives Analysis/DEIS
October 2017 September 2019
2020
FEIS/ROD & Preliminary Design
Final Design & Construction
Operation
COMPLETE Alternatives Analysis/DEIS In-Progress 15% Engineering
2020
In-Progress Final Environmental Impact Statement
2020
In-Progress Draft 20-Year Financial Plan Pending
Final Design & Construction 17
Design Progress – Mall Blvd. Station Locally Preferred Alternative (LPA)
Hyatt House
Atrium
Mall Blvd. Station
18 18
Design Progress – Mall Blvd. Station Locally Preferred Alternative (LPA) 15% Design Progress
Hyatt House
Mall Blvd. Station
Atrium
Mall Blvd. Station
19 19
Design Progress – Mall Blvd. Station 15% Design Refinements
Mall Blvd. Station
Mall Blvd. Station • Streamlined track alignment • Station better serves surrounding properties and provides more opportunity for redevelopment
20
20-Year Financial Plan 20-year Financial Plan & Cash Flow Statement Operating Budget (Five-Year)
Capital Budget
Draft Complete Base Model (20-Year)
(12-Year)
Evaluate Potential Funding Sources
• Following FTA’s Guidance for Transit Financial Plans • Draft to be complete in 2020 21
Return on Investment – KOP Rail Commercial Property Value Anticipated development in King of Prussia generates $260 million in additional commercial property value
22
Return on Investment – KOP Rail
23
Return on Investment – KOP Rail
$2.5 billion total property value premium 24
25
ADRIAN PONSEN CoStar Director of Market Analytics for Philadelphia
King of Prussia Apartment Market Adrian Ponsen, Director of Market Analytics - Philadelphia
CoStar Group Top Public Platforms For Searching & Advertising CRE
700 Million+ Visitors Per Year
Massive Investment In Research & Technology
1,850 Researchers 240 Field Research Vehicles 200 Certified Drone Pilots 1 Airplane
World’s Most Granular CRE Database
5 Million+ Properties 3.9 Million+ Sales Comps 6 Million+ Tenants 560,000+ Available Spaces
Trends in KOP Apartment Development: • Long Under Supplied In High End Apartments • Developers Have Taken A Unique Approach With Focus On Mixed Use/Pedestrian Friendly Amenities • Newly Delivered Apartment Projects Outperforming Broader Philadelphia Market
1954: PA Turnpike & I-80 South
KOP Commercial Real Estate: A Visual History 1960s
1970s
1980s & 90s Source: CoStar
Commercial Inventory (Million Square Feet) King of Prussia
30
Philadelphia County 200
25 160
20
120
15
80
10 5
40
0
0
Source: CoStar
Office
Retail
Industrial/Flex
Multifamily
Source: CoStar
Source: CoStar
Source: CoStar
You Are Here
Source: CoStar
Office Space Per Apartment Unit in 2014 3,500
Square Feet Of Occupied Office Space Per Apartment Unit Within 2-Mile Radius
3,000 2,500 2,000 1,500
1,000 500 0
Montgomery Mall
Source: CoStar
Concord Mall
Bala Cynwyd Shopping Center
Cherry Hill Exton Neshaminy Willow Mall Square Mall Mall Grove Mall
King of Prussia Mall
Plymouth Meeting Mall
Almost 2,000 Units Delivered in KOP Since 2014
Almost 2,000 Units Delivered in KOP Since 2014
The Village At Valley Forge: Before
The Village At Valley Forge: After
KOP Outpacing Center City In Lease-up 25 20
Average Move-Ins Per Month During Leaseup For Multifamily Projects Delivered 2017-18
19.4 16.7
16.4
15.9
15
14.1 11.2
10 5 0 King of Prussia Source: CoStar
Market East
Logan Square/ Art Museum
North Broad
Old City
Main Line
Free Rent Discounts Also Less Common in KOP 30%
% Of Available Units Offering At Least 1 Month Free Rent (Past 24 Months)
20%
10%
0% North Broad
Art Museum/ Fairmount
Analysis only includes properties built after 2010 Source: CoStar
Main Line
Center City
King Of Prussia
Rents Rising Among Most New Projects 2,000
Average Asking Rent (1 Bedroom Units)
1,900 1,800 1,700 1,600 1,500 1,400 AVE King of Prussia
Hanover King of Prussia
Time of Project Completion Source: CoStar
Indigo 301
August 2019
Park Square
The Smith at Valley Forge
Office Space Per Apartment Unit in 2019 3,500
Square Feet Of Occupied Office Space Per Apartment Unit Within 2-Mile Radius
3,000 2,500 2,000 1,500
1,000 500 0
Montgomery Mall
Concord Mall
Exton Square Mall
Includes apartment properties under construction Source: CoStar
Bala Cynwyd Shopping Center
Neshaminy Cherry Hill Mall Mall
Willow King of Plymouth Grove Mall Prussia Mall Meeting Mall
Adrian Ponsen Director of Market Analytics - Philadelphia aponsen@costar.com 215-309-8971
These CoStar Market Analytics materials contain financial and other information from a variety of public and proprietary sources. CoStar Group, Inc. and its affiliates (collectively, “CoStar”) have assumed and relied upon, without independent verification, the accuracy and completeness of such third party information in preparing these materials. The modeling, calculations, forecasts, projections, evaluations, analyses, simulations, or other forward-looking information prepared by CoStar and presented herein (the “Materials”) are based on various assumptions concerning future events and circumstances, which are speculative, uncertain and subject to change without notice. You should not rely upon the Materials as predictions of future results or events, as actual results and events may differ materially. All Materials speak only as of the date referenced with respect to such data and may have materially changed since such date. CoStar has no obligation to update any of the Materials included in this document. You should not construe any of the data provided herein as investment, tax, accounting or legal advice. CoStar does not represent, warrant or guaranty the accuracy or completeness of the information provided herein and shall not be held responsible for any errors in such information. Any user of the information provided herein accepts the information “AS IS” without any warranties whatsoever. To the maximum extent permitted by law, CoStar disclaims any and all liability in the event any information provided herein proves to be inaccurate, incomplete or unreliable. © 2019 CoStar Realty Information, Inc. No reproduction or distribution without permission.
BRIAN O’NEILL MLP Ventures Founder, Chairman & CEO
48
Our Mission Eliminate the barriers between patients and the cures they so desperately need through seamless access to cell and gene therapies
49
What people think of as the moment of discovery is really the discovery of the question.
– Jonas Salk 50
Gene and Cell Therapy Manufacturing Industry Observations
• The average life of a terminally ill patient is 6 months and the average wait for viral vectors is over a year
• The market is substantially supply constrained
• Most current players are generally small scale and fail to center on the customer • There is a lack of integration, organized expertise and capabilities in the fastest growing area of healthcare
• Must be a focus for any company interested in being a leader in biologics • Essential to offer a full end to end offering • Essential to drug developers as they scale and make either the build, buy or rent decision
51
We Are Entering a Therapeutic Revolution
By 2020, US Food and Drug Administration (FDA) officials have said they expect to receive upwards of 200 INDs for cell and gene therapies each year, adding to the 800 active INDs for such products already filed with the agency. By 2025, they predict the agency will be approving between 10 and 20 cell and gene therapy products annually. Alliance for Regenerative Medicine Q2 2019 Report. http://alliancerm.org/wp-content/uploads/2019/07/ARM_Q2_2019_Web_FINAL.pdf
52
Capital is Pouring into Life Sciences and Advanced Therapeutics •
Last year in the United States, $23 billion in capital was invested in 1,300 life sciences companies
•
$173 billion in biopharma M&A occurred during the first half 2019
•
There has been nearly a 50% increase in VC and NIH Funding over the past 5 years
•
Outsized manufacturing demand is being driven by the exponential growth in VC for advanced therapies which grew from $1.4 billion in 2017 to $3.6 billion in 2019 (annualized).
Advanced Therapies Venture Capital Volume
53
However, a Major Backlog in CDMO Capacity • The wait times for CDMOs to start projects now average ≥1.5 years, and are only increasing, with insufficient
CDMOs with technical competence entering the field. Further, new dedicated facilities have yet to be constructed. • The current shortfall in worldwide cell/gene therapy manufacturing capacity may be greater than 5× current
capacity (based on cumulative bioreactor volumetric capacity). • Within five years, when current pipeline products reach clinical scale, unless significant changes occur, the
required platforms and capacity will not be there. • The Discovery Labs is planning over 600,000 square feet of multi-suite plasmid, lentiviral vector, adeno-
associated vector, and CGMP manufacturing capacity to custom produce for clients in its King of Prussia facility.
54
Subscale and Incomplete Competitor Set
5 5
An Advantage Creating Partnership to Take The Market
•
Extensive expertise in building real estate based healthcare organizations and in real estate acquisitions and development
•
Network and history with the brightest architects and engineers
•
1.6 million square feet of life sciences space occupied by the world’s leading companies
•
World class management team
•
3 million square feet of identified CDMO pipeline
•
600,000 square feet of CDMO space under development with 600,000 square feet for expansion
•
Leader in healthcare investment with almost $10bn under management
•
Network of 12 academic partnerships with $2bn of committed capital to seed the gene and cell therapy companies of tomorrow
•
130-person team of field and subject matter experts providing an unmatched perspective on the probabilistic potential of biological innovations
•
Deep pockets to enable The Discovery Labs to disrupt the space
•
Commitment to manufacturing space for its portfolio companies
56
Introducing the Discovery Labs
57
The Discovery Labs The Discovery Labs is a global company bringing together and serving healthcare, life sciences and tech-enabled companies who change the world we live in by discovering and creating lifesaving, life changing and life enhancing products. We have reimagined the workspace and deliver collaborative, innovative, infrastructure-supported, turnkey lab, CGMP manufacturing and oďŹƒce workspaces for healthcare, life sciences and techenabled companies. We are building the largest cell and gene CDMO in the world in King of Prussia We manufacture and supply critical products including plasmids, adeno-associated viral 4s and lentiviral vectors. We provide CDMO services for the cell and gene world. 15
A place where change for the better happens every day
The Discovery Labs is Rolling Out a Global Platform The Discovery Labs initial portfolio includes 1.6 million square feet on 260 acres housed in 27 buildings.
" "
Innovation at Renaissance is 640,000 square feet on 60 acres in 14 buildings on Renaissance Boulevard and Horizon Drive, King of Prussia, PA. The Discovery Labs King of Prussia is 1,000,000 square feet on 200 acres in 12 inner-connected buildings that are supported by a central utility plant on 411 Swedeland Road, King of Prussia, PA.
The Discovery Labs Custom Build Offering includes over 3 million square feet of fully-zoned, infrastructure-in-place build-to-suits in King of Prussia, PA. Our Robust Property Pipeline includes 6 centers for therapeutic break-thru and over a dozen identified targets in the US, Ireland and England in high-demand life sciences clusters.
16
Our 600,000 Square Foot GMP Cell and Gene Therapy Manufacturing operation is the largest in the world and is being constructed that includes multiple suites for advanced therapeutics manufacturing including adeno-associated viral vectors, lentiviral vectors, plasmids and products in King of Prussia, PA. We are identifying sites globally to expand that capability.
The Discovery Labs Offers a Full Range of Products We are solving for the pain points in the path to commercialization so that start-up to enterprise level companies can focus on creating lifesaving products. We provide the following full range of products:
•
Turnkey office and lab space with capacity to grow in place - Chemistry Labs - Biology Labs - Infrastructure-supported, second-generation, pharma-quality labs - CGMP labs - Brand new flex labs
•
High-tech, millennial-centric Coworking and Incubator Space
•
Specialty, client-specific build-to-suits in global locations - Acquisition and retrofit of existing buildings - Ground-up development - Acquisitions of life science and pharma sites to be repositioned to offer services and products to clients
•
Mission critical products including lentiviral vectors, adeno-associated viral vectors and plasmids
•
CGMP production suites manufacturing adeno-associated viruses, lentiviruses and plasmids
•
Customized, made-to-order viral vector manufacturing facilities ranging from a shell to a production-ready facility offering speed to market
18
The Discovery Labs Offers Life Science Coworking and Incubator Space ● Discovery Labs is the first company to offer large scale co-working space to the life science industry
● Our average facility size is nearly 10x the size of our competitor set ● Our space stimulates connection to enhance collaboration ● Our space offering ranges from a bench to a building and everything in-between
19
The Discovery Labs Incubator – Unite IQ ● 23% of life science startups that raised at least $4 million in 2017 and 2018 worked with an accelerator or incubator
● 33% of all startups with Series A funding go through an accelerator or incubator ● Unite IQ, The Discovery Labs incubator, provides the setting and ecosystem to accelerate the translation of technologies from idea to commercialization
● Unite IQ provides lab space, infrastructure, equipment, supplies and support services so that startups can more efficiently deploy capital and resources
● To enhance our ecosystem, Unite IQ and The Discovery Labs partner with companies that have deep expertise in the support, translation and commercialization of life sciences technologies - PA Biotech and the Blumberg Institute - Vivarium Operators - Architect, Consulting and Engineering Firms - On-site helipad for transportation of specimens and samples 20
The Discovery Labs • Optimized to remove the bottlenecks in the path to commercialization by providing key services through all stages in a product’s life cycle
• Our planned 600,000 square foot CGMP cell and gene therapy manufacturing facility is being
constructed with multiple suites for advanced therapeutics manufacturing of all vectors, plasmids and cellular therapy products
• We will directly supply plasmids, viral vectors and cell and gene therapy products as well as operate and lease to third-parties
• Our location pipeline includes over a dozen identified targets in the US, Europe and Asia, specifically in high-demand life sciences clusters
• We are assembling a world-class, high-brand management team with extensive cell and gene therapy manufacturing experience capable of executing perfection at scale
63
Advanced Therapeutics Manufacturing Development Our 600,000 square foot facility for advanced therapeutics manufacturing for gene and cell therapies includes: • 36 suites for advanced cell therapy manufacturing such as CAR T, CAR NK, TCRs, TILs, iPSCs, etc. • 19 Viral Vector suites • 3 Plasmid suites • 20 testing, process development and cell banking suites Suites will have a Universal, Modular, and Flexible Design in order to be adaptable for demand variations, platform differences and technology disruptors including mRNA, electroporation, cell squeezing, piggyBac, allogenic and non-viral vectors.
64
The Discovery Labs Gene and Cell Therapy Manufacturing Plan Campus Map
65
B21 Viral Vector Facility – Typical Floorplan
68
B21 Viral Vector Facility – Typical Floorplan
69
B30 CAR-T Facility – Typical Floorplan Analytics & Kitting Space (1 of 2 per Floor) 2 Patient Suite
Grade B (1 of 8 per floor)
•
•
2 T-Cell Processing Units per Suite + Harvest + Filling Adjacent CRF’s
70
B30 CAR-T Facility – Typical Floorplan People/Material Out Unidirectional Flows
People/Material In
Optional Bidirectional or Unidirectional Flows
71
The Central Utility Plant
72
Products and Services • • • • • • • • • • •
production Plasmid Lentiviral and AAV vector production Cell and gene therapy product manufacturing Custom media optimization, production, sourcing, and testing Process and analytical method development and qualification Large-scale and small-scale closed-system manufacturing and process development and validation Technology transfer of client’s mammalian and insect cell production platforms Downstream process development with chromatographic and filtration-based separation methods Full-range of production platforms including flat stock, iCELLis, 50L-2000L single-use bioreactors, etc. Drug product fill and finish Global quality compliance and regulatory support
• • • • • • • • • • • • • • • • • • • • • • • •
Process Development Cell Line Development GMP Cell Bank Manufacture / Characterization Assay Development, Qualification, and Validation Cell Culture Process Development Purification Process Development Formulation Development Protein Characterization Drug Substance Manufacture Drug Product Formulation and Fill Biosafety Testing (e.g., Viral Clearance) GMP Lot Release Testing Stability Studies Regulatory Support In-Life and Toxicology Studies Discovery Biology Bioanalytical Testing Companion Diagnostic Development Genomics / Genome Sequencing ADME / DMPK Pharmacology / Safety Pharmacology Biosafety Assessment of Raw Materials Extractables & Leachables Testing Sterility Assurance Programs for Products & Facilities 73
One Stop Shop for Ease of FDA Interface • End-to-end view of drug master file and chain of custody under one roof
• Unified quality systems and training in place to ensure FDA readiness from pre-clinical R&D through commercialization
• Unbiased internal SOP examination
• Plans to identify, evaluate, and mitigate compliance risks
• Maintain communication, roles and responsibilities with customers and partners throughout queries and inspections
• Maintain training and documentation to demonstrate competency and readiness
• Maintain a secure and efficient filing system • Post inspection review, consultation, and response 74
Unique and Compelling Sales Process with Sticky Customers Business Development Team • 10 representatives supported by a team of technical experts and strategic integrators who can both MAKE and DELIVER to customer specifications • SEO and SEM activated website and marketing platform Sales Process • Routine and systematic identification of business partnerships and market trends leading to initial contacts • Qualifying a potential business partner by comparing a high level needs assessment against our core competences and acceptable benchmarks • Generate consideration for our service offerings via on-site meetings to show off the technical capabilities and work environment • Thorough technical and financial review of RFP and timely submission to clients • Execution of agreement Drivers of Repeat Business • Meeting client timelines • Meeting client needs • Clear demonstration of technical capabilities • Process development for successful scale up and scale out 75
The Discovery Labs Value Proposition • Integrated preclinical to commercial production • Flexible partnerships • Process development for scale up and scale out • Plasmid and viral vector production • State-of-the-art facilities with dedicated GMP suites for drug production and fill finish • Industry experienced personnel and dedicated project management team • Comprehensive quality system • CMC and DMF documentation support as well as regulatory assistance and support • Necessary space capacity (Suites/Labs/Equipment/Personnel) • Integrated IT and project management systems
76
SITE PLAN
200 ACRE WORLD-CLASS CORPORATE CAMPUS
PENTHOUSES & ROOFTOPS
82
201 KING OF PRUSSIA RD | SUITE 501 RADNOR, PENNSYLVANIA 19087 TEL: 610-239-6100 | FAX: 610-337-5599 BRIAN O’NEILL | 610-992-5860 BONEILL@MLPVENTURES.COM AUDREY GREENBERG| 484-240-5999 AGREENBERG@THEDISCOVERYLABS.COM
83
THIS DOCUMENT IS THE PROPERTY OF THE DISCOVERY LABS, LLC AND/OR ITS AFFILIATES (COLLECTIVELY, “DISCOVERY LABS”) AND IT AND THE INFORMATION IN IT ARE PROVIDED TO CHARLES RIVER LABORATORIES, INC. (“COMPANY”) IN CONFIDENCE PURSUANT TO AND SUBJECT TO THE TERMS OF THE MUTUAL CONFIDENTIALITY AGREEMENT DATED AUGUST 13, 2019 (THE “AGREEMENT”) BETWEEN DISCOVERY LABS AND COMPANY, AND MAY NOT BE DISCLOSED TO ANY THIRD PARTY OR USED FOR ANY PURPOSE OTHER THAN AS SET FORTH IN THE AGREEMENT WITHOUT THE EXPRESS WRITTEN CONSENT OF DISCOVERY LABS.
84
GET $15 OFF KING’S PLATE TICKETS ON OCT. 3 Use code BIG3KING
GET $5 OFF MAIN EVENT TICKETS ON OCT. 5 Use code BIG3MAIN
PRODUCED BY
PRODUCED BY